ILSE Intralase Corp (MM)

IntraLase Corp. (Nasdaq:ILSE) today announced that on Feb. 21, 2006, its executive vice president and chief financial officer, Shelley B. Thunen, adopted a pre-arranged stock trading plan to sell a portion of her company stock over time as part of an individual long-term strategy for asset diversification and liquidity. The stock trading plan was adopted in accordance with guidelines specified under Rule 10b5-1 of the Securities and Exchange Act of 1934 and IntraLase's policies regarding stock transactions. Rule 10b5-1 allows corporate officers and directors to adopt written, pre-arranged stock trading plans when they do not have material, non-public information. Using these plans, insiders can diversify their investment portfolios while avoiding concerns about whether they had material, non-public information when they sold their stock. Under her Rule 10b5-1 Plan, Thunen may sell up to 56,378 shares over a period of approximately five months. These shares, which represent less than 20 percent of Thunen's total IntraLase holdings (including stock options) have been owned by Thunen since 2002. Thunen's Rule 10b5-1 Plan has a series of laddered price triggers for the sale of shares. The transactions under this plan will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission. About IntraLase Corp. IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasties, and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 26 other countries. IntraLase has headquarters and manufactures its products in Irvine. For additional information, visit the company's Web site: www.intralase.com.